Artiva Biotherapeutics (ARTV) Payables (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Payables data on file, last reported at $2.3 million in Q1 2026.

• Payables for Q1 2026 came in at $2.3 million, up 12.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 12.28% YoY), and the FY2025 annual result was $355000.0, down 68.33% from the prior year.
• Payables climbed to $2.3 million in Q1 2026 per ARTV's latest filing, from $355000.0 in the prior quarter.
• Over five years, Payables peaked at $2.3 million in Q1 2026 and troughed at $355000.0 in Q4 2025.
• A 4-year average of $1.2 million and a median of $1.1 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables jumped 82.57% in 2024, then tumbled 68.33% in 2025.
• A 4-year view of Payables shows it stood at $614000.0 in 2023, then soared by 82.57% to $1.1 million in 2024, then plunged by 68.33% to $355000.0 in 2025, then jumped by 543.94% to $2.3 million in 2026.
• Business Quant data shows ARTV's Payables at $2.3 million in Q1 2026, $355000.0 in Q4 2025, and $848000.0 in Q3 2025.